Johnson & Johnson Receives FDA Approval for Monthly RYBREVANT FASPRO Dosing
HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved a new monthly dosing schedule for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), to …
Johnson & Johnson Receives FDA Approval for Monthly RYBREVANT FASPRO Dosing Read More